Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
---|
01/20/2011 | WO2011008947A2 Treatment and diagnosis of immune disorders |
01/20/2011 | WO2011008904A1 Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance |
01/20/2011 | WO2011008730A2 Chemical modification of small hairpin rnas for inhibition of gene expression |
01/20/2011 | WO2011008348A2 Dual vector for inhibition of human immunodeficiency virus |
01/20/2011 | WO2011007859A1 Dna fragment and pharmaceutical composition |
01/20/2011 | WO2011007082A1 Emulsion activatable by ultrasounds and method for producing same |
01/20/2011 | WO2011007007A1 Orally administered bacteria as vehicles for systemic delivery of agents |
01/20/2011 | WO2010093209A3 Use of caveolin-1 as biomarker diagnosing wound healing ability after ophthalmological surgery and method for diagnosing wound healing ability using the same |
01/20/2011 | US20110016547 Use of regulatory sequences for specific, transient expression in neuronal determined cells |
01/20/2011 | US20110016544 Methods and compositions for detecting and treating retinal diseases based on metargidin (ADAM-15) |
01/20/2011 | US20110016538 Susceptibility locus for schizophrenia |
01/20/2011 | US20110015344 Biodegradable polyacetals for in vivo polynucleotide delivery |
01/20/2011 | US20110015257 Hypoxia Inducible VEGF Plasmid for Ischemic Disease |
01/20/2011 | US20110015253 Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
01/20/2011 | US20110014675 Poly zinc finger proteins with improved linkers |
01/20/2011 | US20110014628 Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy |
01/20/2011 | US20110014293 Cleavage kit, and gene therapy by using the same and nucleic acid cleavage detection apparatus |
01/20/2011 | US20110014242 Promoters for expression in modified vaccinia virus ankara |
01/20/2011 | US20110014229 Chimeric flavivirus vectors |
01/20/2011 | US20110014215 Granulysin and uses thereof |
01/20/2011 | US20110014180 Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue |
01/20/2011 | US20110014165 Thymidylate Kinase Mutants and Uses Thereof |
01/20/2011 | US20110014159 Method for obtaining characterized muscle-derived cell populations and uses |
01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
01/20/2011 | CA2767972A1 Dual vector for inhibition of human immunodeficiency virus |
01/19/2011 | EP2275577A1 Nucleic acid compaction method |
01/19/2011 | EP2275575A2 Coding sequence haplotypes of the human BRCA2 gene |
01/19/2011 | EP2275574A2 Coding sequence haplotypes of the human BRCA2 gene |
01/19/2011 | EP2275572A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
01/19/2011 | EP2275571A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
01/19/2011 | EP2275570A2 Identification of surface-associated Antigenes used for the diagnosis and therapy of tumours |
01/19/2011 | EP2275559A2 Optimized messenger RNA |
01/19/2011 | EP2275557A1 Albumin fusion proteins |
01/19/2011 | EP2275554A2 Neisserial antigenic peptides |
01/19/2011 | EP2275553A2 Neisserial antigenic peptides |
01/19/2011 | EP2275552A2 Neisserial antigenic peptides |
01/19/2011 | EP2275551A2 Neisserial antigenic peptides |
01/19/2011 | EP2275548A1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
01/19/2011 | EP2275446A2 Antibodies to insulin-like growth factor I receptor |
01/19/2011 | EP2275118A2 Pancreas-specific proteins |
01/19/2011 | EP2275115A2 Inhibition of stress-induced ligand-dependent EGFR activation |
01/19/2011 | EP2275114A1 Pharmaceutical composition for treating or preventing cancer which induces dendritic cell-like differentiation of monocytes to increase anticancer immune activity |
01/19/2011 | EP2275085A1 Biodegradable copolymer suitable for delivering nucleic acid materials into cells |
01/19/2011 | EP2274324A1 Substances and compositions for enhancing dna repair and methods of use |
01/19/2011 | EP2274001A2 Heat shock protein gp96 vaccination and methods of using same |
01/19/2011 | EP1757312B1 Freeze-dried composition of inactivated virus envelope with membrane fusion activity |
01/19/2011 | EP1409008B1 Use of a nucleic acid molecule coding the disintegrin domain of an adamalysin as anti-angiogenic, anti-invasive and anti-metastatic agent |
01/19/2011 | EP1363997B1 Concentration and lysis of adenovirus-infected cells in a single unit operation |
01/19/2011 | EP1325019B1 Antisense modulation of clusterin expression |
01/19/2011 | EP1252300B1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
01/19/2011 | EP1185296B1 Prevention and treatment of amyloidogenic diseases |
01/19/2011 | CN1814302B Method for selectively increasing tumor cell sensitivity to ionic radiation |
01/19/2011 | CN1809633B Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
01/19/2011 | CN101952433A PTHrP, its isoforms and antagonist thereto in the diagnosis and treatment of disease |
01/19/2011 | CN101948865A Dual-promoter inducible secretable shuttle plasmid and construction method thereof |
01/19/2011 | CN101948859A shRNA expression vector expressed by specificity inhibitor SET protein, construction method and application thereof |
01/19/2011 | CN101948858A RNA (Ribose Nucleic Acid) interference recombination vector of SET (Patient SE Translocation) genes and establishment method and application thereof |
01/19/2011 | CN101948851A Duck-origin coronavirus N protein gene, clone method and application thereof |
01/19/2011 | CN101948841A Epitope sequences |
01/19/2011 | CN101948836A Schistosoma japonicum zinc finger protein coding gene SjZFP1 and application thereof |
01/19/2011 | CN101948834A siRNA for treating HBV |
01/19/2011 | CN101948546A Fusion protein SAmB as well as coding gene and applications thereof |
01/19/2011 | CN101948544A FAT10 gene siRNA recombination analogue virus as well as preparation method and application thereof |
01/19/2011 | CN101948543A Fusion protein and coding gene and application thereof |
01/19/2011 | CN101948516A Establishment and application of vaccinia virus vector-based reverse genetics system |
01/19/2011 | CN101947325A Vibrio paraheamolyticus bivalent DNA vaccine as well as preparation method and application thereof |
01/19/2011 | CN101591655B PKCalpha signal specifically-blocking siRNA and use thereof |
01/19/2011 | CN101120921B Target preparation consisting of liposome and nucleic acid coating contrast agent |
01/18/2011 | US7872119 Antisense strand, sense strand are non-phosphorylated at the 5' and 3' termini; pulmonary, eye, microvascular, hearing disorders; target for hypoxia-inducible factor-1 that may regulate hypoxia-induced pathogenesis independent of growth factors such as VEGF |
01/18/2011 | US7872112 comprising rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A),deoxyhypusine synthase (DHS) nucleic acids and polypeptides; human cytomegalovirus immediate-early promoter/enhancer |
01/18/2011 | US7871986 provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines |
01/18/2011 | US7871983 For therapy and prophylaxis of ischemic diseases, inflammatory diseases, autoimmune diseases, cancer metastasis and invasion, and cachexia |
01/18/2011 | US7871819 recombinant vector comprising a sequence encoding a heterologous polypeptide inserted between E4 and E3 transcription units of an ovine adenovirus genome; directing expression of a coding sequence in a cell; cancer |
01/18/2011 | US7871815 producing a protein by cloning an open reading frame encoding a protein into the nucleic acid sequence of SEQ ID 151, introducing the resulting nucleic acid sequence into a host cell and exposing the host cell to rhamnose, thereby inducing expression of the protein |
01/18/2011 | US7871814 Recombinant bicistronic flaviviruses and methods of use thereof |
01/18/2011 | US7871798 Mammalian cells that express VEGF-D polypeptides |
01/18/2011 | US7871786 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents |
01/18/2011 | US7871603 Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly |
01/18/2011 | CA2455145C Pregnancy-related serine protease |
01/18/2011 | CA2418977C Gene delivery vectors with cell type specificity for primary human chondrocytes |
01/18/2011 | CA2385444C Humanin, a polypeptide suppressing neuronal death |
01/18/2011 | CA2383737C Muc-1 derived peptides |
01/18/2011 | CA2380537C An oncolytic adenovirus |
01/18/2011 | CA2284399C Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
01/18/2011 | CA2260858C Polynucleotide vaccine formulation against pathologies of the horse |
01/13/2011 | WO2011006133A2 Bioengineered silk protein-based nucleic acid delivery systems |
01/13/2011 | WO2011006121A2 Sparc antisense compositions and uses thereof |
01/13/2011 | WO2011006070A2 Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss |
01/13/2011 | WO2011005566A2 Aptamer-targeted sirna to inhibit nonsense mediated decay |
01/13/2011 | WO2011005363A2 Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
01/13/2011 | WO2011004552A1 Water-soluble drug carrier and process for production thereof |
01/13/2011 | WO2011004051A1 Gene therapy compositions for preventing and/or treating autoimmune diseases |
01/13/2011 | WO2011003883A1 Process for the identification of compounds for treating cancer |
01/13/2011 | WO2011003834A1 Amphoteric liposomes comprising imino lipids |
01/13/2011 | WO2011003766A1 Biodegradable copolymer comprising amylopectin or glycogen suitable for delivering nucleic acid materials into cells |
01/13/2011 | WO2011003237A1 Use of two microrna moleculars in lung caner prognosis and medicine preparation |
01/13/2011 | WO2010132047A8 Guanosine/gmp gels and uses thereof |
01/13/2011 | WO2010107740A3 Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
01/13/2011 | WO2010107733A3 Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
01/13/2011 | US20110010785 Products and their use for the diagnosis, prevention and/or care of human and/or animal pathologies characterised by the anomalous deposition of b-amyloid and/or amyloid-like substance in human and/or animal organs and tissues, and screening method for determining the risk of such pathologies |